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Safety and efficacy of Hypofractionated
stereotactic radiosurgery for high-grade
Gliomas at first recurrence: a single-center
experience
Yun Guan1,2,3,4, Ji Xiong5, Mingyuan Pan1,2,3,4, Wenyin Shi6, Jing Li1,2,3,4, Huaguang Zhu1,2,3,4, Xiu Gong1,2,3,4,
Chao Li1,2,3,4, Guanghai Mei1,2,3,4, Xiaoxia Liu1,2,3,4, Li Pan1,2,3,4, Jiazhong Dai1,2,3,4, Yang Wang1,2,3,4,
Enmin Wang1,2,3,4* and Xin Wang1,2,3,4*

Abstract
Background: The optimal treatment for recurrent high-grade gliomas (rHGGs) remains uncertain. This study aimed
to investigate the efficacy and safety of hypofractionated stereotactic radiosurgery (HSRS) as a first-line salvage
treatment for in-field recurrence of high-grade gliomas.
Methods: Between January 2016 and October 2019, 70 patients with rHGG who underwent HSRS were
retrospectively analysed. The primary endpoint was overall survival (OS), and secondary endpoints included both
progression-free survival (PFS) and adverse events, which were assessed according to Common Toxicity Criteria
Adverse Events (CTCAE) version 5. The prognostic value of key clinical features (age, performance status, planning
target volume, dose, use of bevacizumab) was evaluated.
Results: A total of 70 patients were included in the study. Forty patients were male and 30 were female. Forty-nine
had an initial diagnosis of glioblastoma (GBM), and the rest (21) were confirmed to be WHO grade 3 gliomas. The
median planning target volume (PTV) was 16.68 cm3 (0.81–121.96 cm3). The median prescribed dose was 24 Gy
(12–30 Gy) in 4 fractions (2–6 fractions). The median baseline of Karnofsky Performance Status (KPS) was 70
(40–90). With a median follow-up of 12.1 months, the median overall survival after salvage treatment was 17.6
months (19.5 and 14.6 months for grade 3 and 4 gliomas, respectively; p = .039). No grade 3 or higher
toxicities was recorded. Multivariate analysis showed that concurrent bevacizumab with radiosurgery and
KPS > 70 were favourable prognostic factors for grade 4 patients with HGG.
Conclusions: Salvage HSRS showed a favourable outcome and acceptable toxicity for rHGG. A prospective
phase II study (NCT04197492) is ongoing to further investigate the value of hypofractionated stereotactic
radiosurgery (HSRS) in rHGG.
Keywords: Hypofractionated stereotactic radiosurgery, Recurrent high-grade glioma, CyberKnife, Salvage treatment
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Introduction
The most frequently diagnosed malignant primary brain
tumour in adults is high-grade glioma (HGG). In the
United States [1], there are 2.96 newly diagnosed occurrences per 100,000 people per year, while the number in China is up to 5 to 8. Despite definitive primary
therapy, including surgery, adjuvant chemoradiation
and temozolomide-based chemotherapy [2], nearly all
patients experience tumour recurrence [3], up to 90%
of which is local recurrence [4].
The clinical outcome of recurrent rHGG is poor, and
there is no consensus on the optimal treatments, which
consist of surgery, reirradiation systemic therapy and
tumour treating fields (TTFs). Surgery has been reported
to have a median OS of 9.7 months, whereas less than
30% of patients could undergo the operation due to the
involvement of eloquent areas and the infiltrative nature
of glioma [5–7]. Systemic therapy has a median OS ranging from 6 to 9 months [8–10]. The efficacy of salvage
systemic therapy is limited because of the cumulative toxicity and resistance of chemotherapy agents [11]. For TTF,
the median OS reported in EF-14 was 6.6 months [12].
Radiotherapy is also known as an option for rHGG. Several small sample prospective studies reported a promising
outcome and acceptable toxicity with a median OS of 12
to 12.7 months after salvage treatment [13–16].
HSRS can deliver a high radiation dose while limiting
toxicity to normal tissues. CyberKnife is a radiosurgery
system that allows highly conformal image-guided radiotherapy and shows a promising tumour control effect for
central nervous system tumours. This study aims to determine the treatment outcome and toxicity of HSRS.
To our knowledge, this is the largest cohort of rHGGs
treated with HSRS as a first-line salvage treatment.
Methods
Eligibility criteria and endpoints

All participants provided written informed consent, and
studies were approved by the local ethics committee.
Between January 2016 and October 2019, patients with
recurrent HGG who received salvage HSRS using CyberKnife at HuaShan Hospital were included. All patients
had initially histologically confirmed World Health
Organization (WHO) grade 3/4 glioma and received adjuvant external-beam radiation with concomitant temozolomide and adjuvant temozolomide. HGG recurrence
was confirmed by RANO criteria and/or stereotactic
brain biopsy. All patients were treated at first recurrence
within the radiation field.
The primary endpoint was overall survival from the
completion of salvage HSRS (OS-HSRS). The second
endpoints included progression-free survival after salvage treatment and toxicity defined by CTCAE 5.0.
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Baseline evaluation and treatment delivery

HSRS was performed using the Radiosurgery System
(Accuray, Sunnyvale, CA, USA). Patients were immobilized with a custom thermoplastic mask and underwent
both computed tomography (CT, GE Light speed Ultra
16 Slice, USA) examinations with a slice thickness of
1.25 mm and MRI with a slice thickness of 2 mm acquired from both T1 postcontrast and T2 flair images.
CT and MRI scans were then fused using the planning
system for contouring.
Radiation oncologists, neurosurgeons, and radiation
physicists participated in tumour delineation, planning,
and dose selection. Gross tumour volume (GTV) was defined as the gadolinium-enhanced tumour on the T1weighted series. The clinical tumour volume (CTV) was
considered equal to the GTV. The planning target volume (PTV) was a uniform 2 mm expansion of the CTV,
and FLAIR abnormalities were not included in the treatment volume. Multiplan (Accuray, Sunnyvale, CA, USA)
software was used for inverse planning. The prescribed
dose to PTV was determined according to the target volume, site, previous irradiation volume and total dose,
and the interval between treatments.
The use of systemic therapy after HSRS was decided
by the treating physicians. Thus, the regimens were individualized, and most commonly, bevacizumab, temozolomide or clinical trials were recommended.
Assessment and toxicity

All patients underwent clinical and radiological followup every 3 m after HSRS. If any significant deterioration
in the patient’s performance occurred, an MRI was ordered immediately. The radiological examination included MRI and other necessary examinations, such as
MRI-based spectroscopy, perfusion MRI, and methionine positron emission tomography. KPS after treatment,
adverse event occurrence, and associated clinical outcomes were recorded. Toxicity was assessed using the
CTCAE 5.0.
Statistics

The primary outcome was overall survival after HSRS,
defined as survival from the time of the completion of
HSRS to death due to any cause. Other measures included progression-free survival after salvage treatment
and treatment-related toxicities.
Survival curves were estimated using the Kaplan-Meier
method and compared with the log-rank test.
Multivariate analysis of OS-HSRS in WHO grade 4 glioma patients was performed using a Cox proportional
hazards regression model. Variables included in the
multivariate analysis model were those with hypotheses
of interest or determined to be clinically related to survival. Age, PTV, biologically effective dose (the median
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BED was 37.5 Gy, BED was calculated using the LQ
model with an alpha/beta ratio of 10, and KPS and concurrent bevacizumab regimen (defined as bevacizumab
administered during HSRS) were factors included in the
multivariate analysis. The multivariable Cox regression
model results are reported as hazard ratios with 95% CI
and p values. All statistical analyses were performed in R
version 3.6.1 using the survminer and survival packages.
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HSRS was 13.7 months, with a range of 4.2 to 55.3
months.
The median volume of salvage HSRS PTV was 16.68
cm3 (0.81–121.96 cm3). The treatment was given daily,
and the median dose was 24 Gy (12–30 Gy) in 4 fractions (2–6 fractions), with a median isodose line of 70%
(63–75%). Patient characteristics are listed in Table 1.
Compliance and toxicities

Results
Patient characteristics

Between January 2016 and October 2019, 70 high-grade
glioma patients who had clinical, radiographic and/or
stereotactic brain biopsy evidence of recurrence were
treated with CyberKinfe (Fig. 1). All patients were initially treated with maximum safe resection and adjuvant
radiation treatment with a median dose of 60 Gy in 30
fractions with concurrent and maintenance temozolomide. Forty patients were male and 30 were female. The
median age was 53 years (range 20–76 years). The majority of patients (49) had an initial diagnosis of glioblastoma, and the rest (21) had WHO grade 3 gliomas.
The median time from the initial diagnosis to salvage

Fig. 1 Flow diagram of this retrospective study

All patients completed planned HSRS without interruption. There was no significant treatment-related acute
toxicity (grade ≥ 3). Common nonhaematologic grade 2
toxicities included fatigue (9 cases, 12.9%), nausea/
vomiting (7 cases, 10.0%) and headache (4 cases, 5.7%).
Toxicity details are shown in Table 2.
Other toxicities included hypertension, seizure and
haematologic toxicities that were considered chemotherapy related. No complications were related to acute or
late toxicity of HSRS.
Treatment outcomes

By the end of the study, 26 patients died of tumour progression. The median follow-up from the time of HSRS
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Table 1 Baseline Characteristics of All Patients (N = 70)

Table 2 Adverse Events Occurring in rHGG Patients

N

%

Male

40

57

Female

30

43

Parameter

Adverse Events

Total
No. of
Patients

No. of Patients
Grade 1

Grade 2

Grade 3/4

Anaemia

13

8

5

0

Neutropenia

11

5

6

0

Gender

Age, years

Haematologic

Median

53

/

Lymphocytopenia

7

2

5

0

Range

20–76

/

Thrombocytopenia

7

3

4

0

3

21

30

Fatigue

32

23

9

0

4

49

70

Hypertension

21

18

3

0

Headache

21

17

4

0

Initial histological WHO grade

Nonhaematologic

Interval between HSRS and initial diagnosis (months)
Median

13.7

/

Range

1.1–55.3

/

Median

70

/

Range

40–90

KPS before salvage HSRS

Nausea and vomiting

13

6

7

0

Seizure

7

7

0

0

AST* increased

5

2

3

0

ALT† increased

4

1

3

0

Abbreviations: AST aspartate aminotransferase, ALT alanine aminotransferase

MGMT
Unmethylated

25

36

Methylated

9

13

Unknown

36

51

Yes

5

7

No

45

64

Unknown

20

29

Yes

1

1

No

25

36

Unknown

44

63

Median

16.68

/

Range

0.81–121.96

/

14

20

IDH1 mutation

1p19q codeletion

Planning tumour volume (cm3)

Concurrent systemic therapy
TMZ
BVZ

28

40

TMZ + BVZ

7

10

BSC

21

30

70

100

Total

Abbreviations: WHO World Health Organization, HSRS hypofractionated
stereotactic radiosurgery, KPS Karnofsky performance status, MGMT O6methylguanine-DNA methyltransferase, IDH1 Isocitrate dehydrogenase 1, TMZ
Temozolomide, BVZ Bevacizumab, BSC best supportive care

was 12.1 months. The median overall survival after salvage treatment was 17.6 months for the whole cohort
(Fig. 2a, 14.5 to 26.1 months, 95% CI) and 19.5 and 14.6
months for grade 3 and 4 gliomas, respectively (Fig. 2b,
p = 0.039). The overall survival rates following HSRS

were 72.8, 30.1, and 18.0% at 1, 2, and 3 years,
respectively.
All patients were assessed by the RANO criteria, and
42 patients had progressive disease. Twelve of the patients (28.6%) had new lesions outside the radiation field,
and 30 patients (71.4%) had local recurrence (LR). The
6-month PFS was 76.3 and 57.1% for grade 3 and 4 patients, respectively. The median PFS was 7.0 months (5.9
to 9.2 months, 95% CI) and 7.6 and 6.8 months for
grades 3 and 4, respectively (p = 0.077). Twenty-four patients received a second-course salvage treatment because of radiographic progression, and two of them
received surgery.
On multivariate analysis, KPS > 70 (HR = 0.13, p =
0.0060) and bevacizumab concurrently administered
with HSRS (defined as bevacizumab administered during
HSRS, HR = 0.15, p = 0.0040) were factors that positively
affected OS after salvage HSRS for grade 4 patients
(Table 3). The one-year OS rates after HSRS in grade 4
patients who had concurrent bevacizumab with HSRS
and those who did not were 77.3 and 56.0%, respectively
(Fig. 2c, p = 0.035). Grade 4 patients with a KPS > 70 before treatment also showed a longer OS than those with
a KPS ≤ 70 (Fig. 2d, p = 0.041).
There was no significant difference in age, sex, KPS,
mutation status, time from the initial diagnosis to HSRS
or PTV between these two groups.

Discussion
Salvage treatment options for recurrent high-grade
Glioma

For rHGG patients, salvage treatment included surgery,
reirradiation, systemic therapy, and TTF. Although the
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Fig. 2 a Survival time from salvage HSRS (OS-HSRS) of all rHGG patients; b OS-HSRS for WHO Grade 3 and 4 patients; c OS-HSRS for WHO Grade
4 patients who underwent concurrent bevacizumab with HSRS; d OS-HSRS for WHO Grade 4 patients who had KPS ≤ 70 v > 70

results of prospective trials on these regimens have been
published (Table 4), no standard treatment exists [9, 12,
16]. Thus, an individualized option that considers efficacy, quality of life and toxicity is crucial.
The efficacy of systemic therapy in improving OS for
rHGG is unclear. Bevacizumab improved PFS with a median OS of 9 months in two randomized controlled trials
Table 3 Multivariate Analysis of Survival after Salvage Treatment
in Grade 4 rHGG Patients
Factors

Comparison

Age, years

Continuous

KPS

> 70 v ≤ 70

PTV, cm

> 10 v ≤ 10

BED, Gy

> 37.5 v ≤ 37.5
Yes v no

3

†

Concurrent bevacizumab

95%CI

P

1.03

0.98–1.08

0.250

0.13

0.03–0.56

0.006

0.44

0.13–1.50

0.187

1.50

0.53–4.27

0.446

0.15

0.04–0.56

0.004

HR

Abbreviations: HR hazard ratio, CI confidence interval, KPS Karnofsky
performance status, PTV planning target volume, BED biologically
effective dose
*BED was calculated using the LQ model with an alpha/beta ratio of 10
†Concurrent was defined as bevacizumab administered with HSRS

(RCTs) [9, 10]. Programmed death-1 (PD-1) immune
checkpoint inhibitor antibody showed a negative result
compared with bevacizumab, with a median OS of 9.8
months and median PFS of 1.5 months in the phase III
RCT Checkmate 143 trial [8].
HSRS and hypofractionated stereotactic radiotherapy
(HSRT) using linear accelerators take advantage of the
stereotactic precision as well as the properties of a
standard fractionation schedule. Irradiated recurrent tumours allow a high treatment dose to cover the PTV
and minimize normal brain toxicity. In addition, the
condensed treatment schedule could be an important
option for rHGG patients with short expected survival
and poor KPS. HSRT has been reported to have a median overall survival for rHGG patients ranging from 12
to 12.7 months. Conti et al. reported a median survival
of 12 months for recurrent glioblastoma patients who
underwent HSRS reirradiation with temozolomide 75
mg/m2/day for 21 days every 28 days [17]. The prospective trial by Wuthrick reported a median survival of 12.7
months in grade 4 glioma patients using HSRT of 30 to
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Table 4 Recent Prospective Trials of Recurrent High-grade Glioma
Treatment

Author, Year

Regimen

Median Dose(Gy)

Sample Size(N)

MST (Months)

Systemic Therapy

Reardon, 2017 [8]

Nivolumab vs BVZ

N/A

Nivo = 184 BVZ = 185

9.8 vs 10.0

Wick, 2017 [9]

Lomustine +BVZ vs Lomustine

N/A

L + BVZ = 228 L = 149

9.1 vs 8.6

TTF
HSRT

Friedman, 2009 [10]

BVZ vs BVZ + CPT11

N/A

BVZ = 85 BVZ + CPT11 = 82

9.2 vs 8.7

Stupp, 2012 [12]

TTField vs Chemotherapy

N/A

TTF = 120 Chemotherapy = 117

6.6 vs 6

Clarke, 2017 [13]

HSRT+BVZ

30

15

12.5

Miwa, 2014 [14]

HSRT+TMZ

30

21

12.0

Wuthrick, 2014 [15]

HSRT+Sunitinib

35

11

12.7(GBM)

Abbreviations: TTF Tumor Treatment Field, HSRT Hypofractionated stereotactic radiotherapy, BVZ Bevacizumab, TMZ Temozolomide, GBM Glioblastoma Multiforme

42 Gy in 2.5 to 3.75 Gy fractions with 37.5 daily sunitinib
[15]. Fogh et al. reported the largest series retrospective
study of 147 patients using X-knife with a median dose
of 35 Gy in 10 fractions. The median survival achieved
11 months [18]. Additionally, Shi et al. reported a cohort
of 36 grade 2 to 4 glioma patients using 30–35 Gy/10 fx
HSRT with alisertib who achieved a median overall survival of 11.1 months [19].
There are limited data addressing the combination of
systematic therapy and reirradiation for rHGG [20]. Several prospective trials examined the safety and efficacy of
HSRT with systematic therapy for rHGG exhibiting OS
ranging from 12 months to 12.7 months (Table 4). Minniti et al. examined HSRT with TMZ in 54 rHGG patients. With 30 Gy in 5 fractions plus concomitant TMZ
up to 12 cycles, the median survival after salvage treatment was 12.4 months. KPS > 70 and grade 3 glioma
were considered prognostic factors for survival [16].

Effectiveness of CyberKnife re-irradiation for rHGG

CyberKnife is an image-guided stereotactic radiosurgery
system that can deliver accurate treatment doses to
brain lesions. In this study, we showed a median OS
after HSRS of 17.6 months (19.5 and 14.6 months for
grade 3 and 4 gliomas, respectively; p = 0.039). In the literature, the survival of grade 4 patients after CyberKnife
was reported to range from 10.6 to 13.7 months [21, 22].
The promising survival in this study is due to several
reasons. First, radiation was delivered with a relatively
low isodose line of 63 to 75% and resulted in a higher
dose delivered to the tumour. It increased the tumour
centre dose and enhanced the tumour cell killing activity
as a direct result as Romanelli et al. reported that the
normalized total dose can achieve 57 Gy (24 Gy in 3
fractions 80% isodose) for the tumour using an α/β = 10
linear quadratic model [23]. Second, all the enrolled patients received HSRS as first-line salvage treatment. For
these patients, survival was expected to be longer. Third,
24 (34.2%) patients underwent a second-course salvage
treatment after HSRS, including surgery, HSRS, systemic
therapy, and TTF.

Minimizing radiation injury to the normal brain was
considered when increasing the treatment dose. Bevacizumab is an anti-vascular endothelial growth factor
(VEGF) monoclonal antibody that is used in recurrent
glioblastoma [9, 10]. Bevacizumab has been hypothesized
to protect the normal brain from radiation by reducing
brain oedema and radiation necrosis. The advantage of
adding bevacizumab to HSRS has not been fully illustrated. Philip el al theorized that the additional bevacizumab sensitized the tumour endothelia to radiotherapy
and induced apoptosis [24]. Additionally, Kyle et al. concluded that the perivascular niche and antitumour effects could be the reason.
Our data suggest that HSRS with concomitant bevacizumab and good performance status result in improved
survival in grade 4 patients. These results are similar to
Sharma’s research that reported 53 GBM patients who
achieved a median survival of 11 months after gamma
knife radiosurgery, and radiosurgery was associated with
longer survival in good performance patients [25].
Additionally, Cuneo reported an OS of 11.2 months in
patients receiving bevacizumab and stereotactic radiosurgery compared with 3.9 months for patients treated
with stereotactic radiosurgery alone [26]. However, the
preliminary results of RTOG1205 showed a negative result
of HSRT in improving OS [27]. A variety of radiotherapy
techniques used in the trial and a relatively larger median
PTV may contaminate the result. However, an improved
6-month PFS was achieved in the HSRT+BVZ group compared with the BVZ only group, and a longer PFS can increase the quality of life in brain tumour patients. For
rHGG patients who have few or other therapeutic options,
HSRS or HSRT combined with bevacizumab may represent a reasonable consideration.

Strengths and limitations

To date, this is the largest cohort of CyberKnife as a
first-line salvage treatment for recurrent high-grade glioma within radiation field patients. Our study demonstrates promising survival and mild toxicity using
CyberKnife radiosurgery for rHGG patients.
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However, the retrospective nature limited this study.
Selection bias was created when deciding the eligible patients for salvage treatment, which increased the number
of potential good prognosis patients. Additionally, additional systemic therapy, second-course salvage treatment after HSRS and lack of imaging follow-up for
palliative care patients may influence the result. Moreover, both previous studies and clinical experience at
our centre [see Additional file 2] encountered the same
dilemma as irradiated brain tumours, and the diagnosis
of LR and RN was difficult [28, 29].
Despite the limitations, this study presented a promising
outcome of salvage HSRS. A prospective phase II study
HSCK-002 ClinicalTrials.gov identifier, NCT04197492, is
ongoing at our centre to further investigate the value of
HSRS and anlotinib (an oral novel multitarget tyrosine
kinase inhibitor targeting VEGF receptor, fibroblast
growth factor receptor and platelet-derived growth factor
receptor).

Conclusions
HSRS using the CyberKnife radiosurgery system showed
a favourable outcome and acceptable toxicity as a salvage
treatment for HGG at first recurrence. A prospective
phase II trial, HSCK-002 (ClinicalTrials.gov identifier:
NCT04197492), is ongoing to further evaluate the efficacy
of CyberKnife radiosurgery for rHGG.
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s12885-021-07856-y.
Additional file 1. Treatment of progression after CyberKnife
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